Due to high demand, Eurofins is hosting additional Webinars to help stakeholders across the food industry respond to horse meat scandal

Eurofins Scientific (EUFI.PA), the global leader in food and feed testing, is hosting several Focal Point Webinars on Friday, the 22^nd of February, 2013, for an interactive discussion of the issues related to the ongoing horse meat scandal in Europe. Following the oversubscription for the first webinars scheduled at 11h00 CET (in German) and 14h00 CET (in English), Eurofins will be hosting a third one at 16h00 CET (in English).

Experts across the Eurofins Group will be on hand to answer any questions from clients and other participants in the live event. Topics to be covered include meat speciation, detection of veterinary drug residues and other contaminants, analytical methods, compliance with existing and emerging food safety regulations, and any other subjects that participants wish to address related to the current meat industry developments in Europe.

The principal goal of this specific webinar is to provide all interested stakeholders in the food supply chain assistance in (i) determining the most important issues from the horsemeat scandal relevant to them; (ii) complying with existing and new regulations; and (iii) improving risk management in clients' production chain.

Carmen Diaz-Amigo, Director for Conference Management at Eurofins says: "With our Focal Point Webinar services, we help our customers obtain all relevant information instantly. We gather our experts to answer all questions live and on the spot. This has shown to be greatly appreciated during food industry crises such as the present meat scandal. Better information leads to better protection for clients, and ultimately better protection for consumers".

For details of all upcoming webinars and short trailers of past webinars, please visit http://www.eurofins.de/conferences_en/webinars/upcoming-webinars/authenticity-22022013.aspx

For more information, please visit www.eurofins.com or contact:

Notes for the editor:

Eurofins - a global leader in bio-analysis

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services.

With over 13,000 staff in more than 170 laboratories across 34 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high-quality services, accurate results in time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.